{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:01Z","timestamp":1761888241653,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia (English Edition)"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.repce.2021.11.017","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T15:46:19Z","timestamp":1639583179000},"page":"975-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper"],"prefix":"10.1016","volume":"40","author":[{"given":"Jos\u00e9","family":"Silva-Cardoso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e2ndida","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Morais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repce.2021.11.017_bib0320","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0325","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association atlas: heart failure epidemiology and management statistics 2019","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0330","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.repce.2021.11.017_bib0335","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/CIRCHEARTFAILURE.114.001957","article-title":"Relief and recurrence of congestion during and after hospitalization for acute heart failure","volume":"8","author":"Lala","year":"2015","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0340","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1021\/ja01565a079","article-title":"Benzothiadiazine dioxides as novel diuretics","volume":"79","author":"Novello","year":"1957","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.repce.2021.11.017_bib0345","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/archinte.1960.03860170024006","article-title":"Diuretic action of furosemide","volume":"115","author":"Hutcheon","year":"1965","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0350","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1055\/s-0028-1112283","article-title":"[Experimental studies and clinical trials of a new diuretic]","volume":"88","author":"Kleinfelder","year":"1963","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.repce.2021.11.017_bib0355","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0360","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial \u2013 the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.repce.2021.11.017_bib0365","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"90","author":"CIBIS Investigators and Committees","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.repce.2021.11.017_bib0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0375","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0380","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0385","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0390","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"2019 ACC Expert Consensus Decision Pathway on Risk Assessment Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"74","author":"Hollenberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"year":"2020","series-title":"CareMe HF algorithm [Internet]","author":"British Cardiovascular Society","key":"10.1016\/j.repce.2021.11.017_bib0395"},{"key":"10.1016\/j.repce.2021.11.017_bib0400","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0405","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.repce.2021.11.017_bib0410","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199001113220206","article-title":"Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure","volume":"322","author":"Katz","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0415","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repce.2021.11.017_bib0420","article-title":"Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients","author":"Kapelios","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.repce.2021.11.017_bib0425","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0430","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jacc.2010.09.046","article-title":"Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice","volume":"57","author":"Fabritz","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repce.2021.11.017_bib0435","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1161\/CIRCRESAHA.116.304937","article-title":"Mechanotransduction in cardiac hypertrophy and failure","volume":"116","author":"Lyon","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.repce.2021.11.017_bib0440","series-title":"Cochrane database of systematic reviews","article-title":"Diuretics for heart failure","author":"Faris","year":"2012"},{"key":"10.1016\/j.repce.2021.11.017_bib0445","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.repce.2021.11.017_bib0450","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12872-020-01384-6","article-title":"Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study","volume":"20","author":"Kurgansky","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.repce.2021.11.017_bib0455","doi-asserted-by":"crossref","first-page":"e8431","DOI":"10.1097\/MD.0000000000008431","article-title":"Heart rate and outcomes in patients with heart failure with preserved ejection fraction","volume":"96","author":"Shang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.repce.2021.11.017_bib0460","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.repce.2021.11.017_bib0465","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.repce.2021.11.017_bib0470","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0475","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0480","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0485","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.repce.2021.11.017_bib0490","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin\u2013angiotensin\u2013aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0495","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","article-title":"Management of RAASi-associated hyperkalemia in patients with cardiovascular disease","volume":"26","author":"Silva-Cardoso","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.repce.2021.11.017_bib0500","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.repce.2021.11.017_bib0505","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 2","key":"10.1016\/j.repce.2021.11.017_bib0510","article-title":"Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF","volume":"41","author":"Kristensen","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repce.2021.11.017_bib0515","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal Effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0520","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0525","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.106.687103","article-title":"Prediction of mode of death in heart failure","volume":"116","author":"Mozaffarian","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.repce.2021.11.017_bib0530","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014240","article-title":"Clinical implications of the New York Heart Association Classification","volume":"8","author":"Caraballo","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repce.2021.11.017_bib0535","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.repce.2021.11.017_bib0540","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin\u2013receptor\u2013neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repce.2021.11.017_bib0545","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0550","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repce.2021.11.017_bib0555","article-title":"Acute heart failure diagnosis and management \u2013 Clinical Guidance 187","author":"NICE (National Institute for Health and Care Excellence)","year":"2020","journal-title":"Natl Inst Heal Care Excell"},{"key":"10.1016\/j.repce.2021.11.017_bib0560","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.repce.2021.11.017_bib0565","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repce.2021.11.017_bib0570","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.repce.2021.11.017_bib0575","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repce.2021.11.017_bib0580","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repce.2021.11.017_bib0585","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.repce.2021.11.017_bib0590","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehaa1061","article-title":"The year in cardiovascular medicine 2020: heart failure and cardiomyopathies","volume":"42","author":"Bueno","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repce.2021.11.017_bib0595","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ehf2.13237","article-title":"Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry","volume":"8","author":"Cowie","year":"2021","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0600","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.repce.2021.11.017_bib0605","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin\u2013angiotensin\u2013aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0610","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol (England)"},{"key":"10.1016\/j.repce.2021.11.017_bib0615","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repce.2021.11.017_bib0620","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.repce.2021.11.017_bib0625","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.repce.2021.11.017_bib0630","first-page":"7","article-title":"The future of telemedicine in the management of heart failure patients","volume":"28","author":"Silva-Cardoso","year":"2021","journal-title":"Card Fail Rev"}],"container-title":["Revista Portuguesa de Cardiologia (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2174204921003706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2174204921003706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:42:05Z","timestamp":1761882125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2174204921003706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2174204921003706"],"URL":"https:\/\/doi.org\/10.1016\/j.repce.2021.11.017","relation":{},"ISSN":["2174-2049"],"issn-type":[{"type":"print","value":"2174-2049"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repce.2021.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2021.07.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}